{"id":24388,"date":"2026-08-20T10:48:10","date_gmt":"2026-08-20T03:48:10","guid":{"rendered":"https:\/\/www.nanovest.io/blog\/?p=24388"},"modified":"2026-08-20T10:48:10","modified_gmt":"2026-08-20T03:48:10","slug":"vaksin-kanker-moderna-merck-lolos-uji","status":"publish","type":"post","link":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/","title":{"rendered":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Teknologi mRNA kembali menjadi perhatian Wall Street, kali ini bukan karena vaksin penyakit menular. <\/span><a href=\"https:\/\/nanovest.go.link\/page=IndividualStockDetail?action=navigate&amp;is_param=true&amp;symbol=MRNA&amp;adj_t=1rhus2a1&amp;adj_deep_link=nanovest%3A%2F%2Fpage%3DIndividualStockDetail%3Faction%3Dnavigate%26is_param%3Dtrue%26symbol%3DMRNA\"><span style=\"font-weight: 400;\">Moderna (MRNA)<\/span><\/a><span style=\"font-weight: 400;\"> dan <\/span><a href=\"https:\/\/nanovest.go.link\/page=IndividualStockDetail?action=navigate&amp;is_param=true&amp;symbol=MRK&amp;adj_t=1rhus2a1&amp;adj_deep_link=nanovest%3A%2F%2Fpage%3DIndividualStockDetail%3Faction%3Dnavigate%26is_param%3Dtrue%26symbol%3DMRK\"><span style=\"font-weight: 400;\">Merck (MRK)<\/span><\/a><span style=\"font-weight: 400;\"> mengumumkan hasil awal positif dari uji klinis Fase 3 vaksin kanker personalisasi untuk melanoma, membawa terapi tersebut selangkah lebih dekat menuju potensi pengajuan persetujuan regulator.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Kombinasi vaksin eksperimental berbasis mRNA milik Moderna dengan imunoterapi Keytruda dari Merck berhasil mencapai tujuan utama penelitian pada lebih dari 1.100 pasien melanoma berisiko tinggi atau stadium lanjut yang tumornya telah diangkat sepenuhnya melalui operasi.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Pasar merespons dengan sangat agresif. Saham Moderna melonjak sekitar 177% pada Rabu (19\/8) dan mencapai level tertinggi sejak 2023. Saham Merck juga naik lebih dari 12% setelah hasil penelitian diumumkan.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Lonjakan Moderna bahkan ikut mengangkat sektor kesehatan AS di tengah perdagangan Wall Street yang secara keseluruhan hanya menguat tipis.<\/span><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_86 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Daftar Isi <\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#Vaksin_Kanker_Capai_Target_Utama_Uji_Fase_3\" >Vaksin Kanker Capai Target Utama Uji Fase 3<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#MRNA_Meroket_177_Pasar_Melihat_Peluang_Lebih_Besar\" >MRNA Meroket 177%, Pasar Melihat Peluang Lebih Besar<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#Persetujuan_Regulator_Jadi_Tahap_Berikutnya\" >Persetujuan Regulator Jadi Tahap Berikutnya<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Vaksin_Kanker_Capai_Target_Utama_Uji_Fase_3\"><\/span><b>Vaksin Kanker Capai Target Utama Uji Fase 3<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Hasil Fase 3 menunjukkan kombinasi vaksin kanker Moderna dan Keytruda secara signifikan memperpanjang waktu hidup pasien tanpa mengalami kekambuhan melanoma dibandingkan penggunaan Keytruda saja.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Terapi tersebut juga mengurangi risiko kanker menyebar ke bagian tubuh yang jauh. Hasil ini memperkuat data positif dari uji Fase 2 sebelumnya dan menjadi perkembangan penting karena melanoma merupakan bentuk kanker kulit yang paling mematikan, meskipun hanya menyumbang sekitar 1% dari keseluruhan kasus kanker kulit.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Pendekatan Moderna dan Merck berbeda dari vaksin konvensional. Setiap vaksin dibuat secara personal berdasarkan mutasi spesifik pada tumor masing-masing pasien.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Secara sederhana, vaksin tersebut dirancang untuk melatih sistem kekebalan agar mengenali penanda unik dari sel kanker pasien. Respons tersebut kemudian dikombinasikan dengan Keytruda, yang membantu sistem imun menyerang sel kanker dengan lebih efektif.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Studi masih berlangsung untuk mengevaluasi indikator lain, termasuk <\/span><i><span style=\"font-weight: 400;\">overall survival <\/span><\/i><span style=\"font-weight: 400;\">atau kemampuan terapi memperpanjang kelangsungan hidup pasien secara keseluruhan. Moderna dan Merck berencana mempresentasikan data lebih lengkap pada pertemuan medis internasional mendatang.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"MRNA_Meroket_177_Pasar_Melihat_Peluang_Lebih_Besar\"><\/span><b>MRNA Meroket 177%, Pasar Melihat Peluang Lebih Besar<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Besarnya respons saham Moderna menunjukkan bahwa investor tidak hanya melihat hasil tersebut sebagai kemajuan untuk satu terapi melanoma.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Saham MRNA ditutup melonjak sekitar 176,97%, sementara kapitalisasi pasar perusahaan berada di kisaran US$25 miliar sebelum lonjakan tersebut. Sebagai perbandingan, Merck memiliki kapitalisasi pasar sekitar US$333 miliar sehingga respons sahamnya lebih moderat meskipun sama-sama mendapatkan katalis positif.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Bagi Moderna, hasil Fase 3 ini menjadi penting karena dapat memperluas penggunaan teknologi mRNA yang selama ini identik dengan vaksin Covid-19 menuju pengobatan kanker yang dipersonalisasi.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Potensinya juga tidak berhenti pada melanoma. Moderna dan Merck tengah menguji pendekatan serupa terhadap beberapa jenis tumor lain, termasuk kanker paru-paru non-sel kecil, kanker kandung kemih, dan karsinoma sel ginjal.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dengan demikian, keberhasilan pada melanoma dapat menjadi validasi awal bahwa platform tersebut berpotensi diterapkan lebih luas. Namun, efektivitas pada jenis kanker lain tetap harus dibuktikan melalui masing-masing uji klinis.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Persetujuan_Regulator_Jadi_Tahap_Berikutnya\"><\/span><b>Persetujuan Regulator Jadi Tahap Berikutnya<\/b><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Meski hasil Fase 3 menjadi tonggak penting, vaksin kanker Moderna dan Merck belum mendapatkan persetujuan untuk dipasarkan.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Kedua perusahaan diperkirakan mulai berdiskusi dengan regulator mengenai data efektivitas dan keamanan dalam beberapa bulan mendatang. Belum ada jadwal resmi mengenai kapan permohonan persetujuan di Amerika Serikat akan diajukan.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Investor juga masih perlu menunggu data lengkap dari penelitian, termasuk hasil <\/span><i><span style=\"font-weight: 400;\">overall survival<\/span><\/i><span style=\"font-weight: 400;\">. Faktor keamanan, proses manufaktur vaksin yang harus dipersonalisasi untuk setiap pasien, hingga potensi penggunaannya pada jenis kanker lain akan menentukan seberapa besar peluang komersial terapi tersebut.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Bagi Moderna, perkembangan ini sekaligus menjadi ujian penting bagi strategi perusahaan memperluas teknologi mRNA ke luar vaksin penyakit menular. Sementara bagi Merck, terapi tersebut berpotensi memperkuat ekosistem Keytruda dengan pendekatan kanker personalisasi baru.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Setelah saham MRNA melonjak 177% hanya dalam satu sesi, perhatian berikutnya akan bergeser dari euforia hasil uji klinis menuju data lengkap, proses regulasi, dan kemampuan Moderna-Merck membuktikan bahwa teknologi tersebut dapat berkembang menjadi platform terapi kanker yang lebih luas.<\/span><\/p>\n<div style=\"background: linear-gradient(135deg, #111827, #1F2937); padding: 28px; border-radius: 18px; margin: 30px 0; color: #ffffff; text-align: center; box-shadow: 0 10px 30px rgba(0, 0, 0, 0.18);\">\n<p style=\"margin: 0 0 12px; color: #ffffff; font-size: 28px; line-height: 1.3;\"><strong>Pantau Peluang di Saham Healthcare AS<\/strong><\/p>\n<p style=\"max-width: 720px; margin: 16px auto 26px; color: #e5e7eb; font-size: 16px; line-height: 1.7;\">Hasil uji klinis dapat menjadi katalis besar bagi saham bioteknologi dan farmasi. Pantau saham AS melalui Nanovest dan ikuti perkembangan healthcare, earnings, serta Wall Street terbaru lewat News dan Artikel Tips Nanovest.<\/p>\n<div style=\"display: flex; flex-wrap: wrap; justify-content: center; gap: 14px;\">\n<p><a style=\"display: inline-flex; align-items: center; justify-content: center; min-width: 190px; padding: 14px 24px; border-radius: 10px; background: #7C3AED; color: #ffffff; font-size: 15px; font-weight: bold; text-decoration: none; box-shadow: 0 6px 16px rgba(0, 0, 0, 0.18);\" href=\"https:\/\/nanovest.io\" target=\"_blank\" rel=\"noopener noreferrer\">Investasi di Nanovest<\/a><\/p>\n<p><a style=\"display: inline-flex; align-items: center; justify-content: center; min-width: 190px; padding: 14px 24px; border-radius: 10px; background: #ffffff; color: #7c3aed; font-size: 15px; font-weight: bold; text-decoration: none; box-shadow: 0 6px 16px rgba(0, 0, 0, 0.12);\" href=\"https:\/\/nanovest.io\/blog\/\" target=\"_blank\" rel=\"noopener noreferrer\">Baca News &amp; Artikel Tips<\/a><span style=\"color: #333333;\">\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Teknologi mRNA kembali menjadi perhatian Wall Street, kali ini bukan karena vaksin penyakit menular. Moderna (MRNA) dan Merck (MRK) mengumumkan hasil awal positif dari uji klinis Fase 3 vaksin kanker personalisasi untuk melanoma, membawa terapi tersebut selangkah lebih dekat menuju potensi pengajuan persetujuan regulator. Kombinasi vaksin eksperimental berbasis mRNA milik Moderna dengan imunoterapi Keytruda dari<\/p>\n","protected":false},"author":35,"featured_media":24389,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[80,39],"tags":[74,28,52,29],"class_list":["post-24388","post","type-post","status-publish","format-standard","has-post-thumbnail","category-berita","category-saham-as","tag-berita","tag-saham-amerika","tag-saham-as","tag-us-stocks"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO Pro 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Vaksin kanker personalisasi Moderna dan Merck mencatat hasil positif dalam uji Fase 3 melanoma. Saham MRNA meroket 177%, sementara MRK ikut menguat.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Maretha Putri\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"id_ID\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Blog Nanovest - Artikel dan Berita Kripto, Saham AS, dan Emas\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita\" \/>\n\t\t<meta property=\"og:description\" content=\"Vaksin kanker personalisasi Moderna dan Merck mencatat hasil positif dalam uji Fase 3 melanoma. Saham MRNA meroket 177%, sementara MRK ikut menguat.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-08-20T03:48:10+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-08-20T03:48:10+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nanovest\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@nanovest_io\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Vaksin kanker personalisasi Moderna dan Merck mencatat hasil positif dalam uji Fase 3 melanoma. Saham MRNA meroket 177%, sementara MRK ikut menguat.\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@nanovest_io\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.nanovest.io/blog\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/category\\\/berita\\\/#listItem\",\"name\":\"Berita\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/category\\\/berita\\\/#listItem\",\"position\":2,\"name\":\"Berita\",\"item\":\"https:\\\/\\\/www.nanovest.io/blog\\\/category\\\/berita\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#listItem\",\"name\":\"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#listItem\",\"position\":3,\"name\":\"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/category\\\/berita\\\/#listItem\",\"name\":\"Berita\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#newsarticle\",\"name\":\"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita\",\"headline\":\"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3\",\"author\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/maretha\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp\",\"width\":1536,\"height\":1024,\"caption\":\"Bottle labeled 'Personalized mRNA Cancer Vaccine' on a lab bench with a shield graphic; DNA strand nearby and a muscular figure in the background, science imagery suggesting cancer treatment research.\"},\"datePublished\":\"2026-08-20T10:48:10+07:00\",\"dateModified\":\"2026-08-20T10:48:10+07:00\",\"inLanguage\":\"id-ID\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#webpage\"},\"articleSection\":\"Berita, Saham AS, Berita, Saham Amerika, Saham AS, US Stocks\",\"dateline\":\"Published on Agustus 20, 2026.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#organization\",\"name\":\"Nanovest\",\"description\":\"Artikel dan Berita Kripto, Saham AS, dan Emas\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/site-logo-color.png\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#organizationLogo\",\"width\":250,\"height\":250,\"caption\":\"site-logo-color\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/nanovest\",\"https:\\\/\\\/twitter.com\\\/nanovest_io\",\"https:\\\/\\\/www.instagram.com\\\/nanovest.io\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC5Y5fD2FApTWMc0c2mlxzIg\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nano-vest\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/maretha\\\/#author\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/maretha\\\/\",\"name\":\"Maretha Putri\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#authorImage\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-ChatGPT-Image-Apr-6-2026-12_10_31-PM-96x96.png\",\"width\":96,\"height\":96,\"caption\":\"Maretha Putri\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#webpage\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/\",\"name\":\"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita\",\"description\":\"Vaksin kanker personalisasi Moderna dan Merck mencatat hasil positif dalam uji Fase 3 melanoma. Saham MRNA meroket 177%, sementara MRK ikut menguat.\",\"inLanguage\":\"id-ID\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/maretha\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/author\\\/maretha\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#mainImage\",\"width\":1536,\"height\":1024,\"caption\":\"Bottle labeled 'Personalized mRNA Cancer Vaccine' on a lab bench with a shield graphic; DNA strand nearby and a muscular figure in the background, science imagery suggesting cancer treatment research.\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/berita\\\/vaksin-kanker-moderna-merck-lolos-uji-24388\\\/#mainImage\"},\"datePublished\":\"2026-08-20T10:48:10+07:00\",\"dateModified\":\"2026-08-20T10:48:10+07:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.nanovest.io/blog\\\/\",\"name\":\"Nanovest\",\"alternateName\":\"Blog Nanovest\",\"description\":\"Artikel dan Berita Kripto, Saham AS, dan Emas\",\"inLanguage\":\"id-ID\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nanovest.io/blog\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO Pro -->\r\n\t\t<title>Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita<\/title>\n\n","aioseo_head_json":{"title":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita","description":"Vaksin kanker personalisasi Moderna dan Merck mencatat hasil positif dalam uji Fase 3 melanoma. Saham MRNA meroket 177%, sementara MRK ikut menguat.","canonical_url":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog#listItem","position":1,"name":"Home","item":"https:\/\/www.nanovest.io/blog","nextItem":{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/category\/berita\/#listItem","name":"Berita"}},{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/category\/berita\/#listItem","position":2,"name":"Berita","item":"https:\/\/www.nanovest.io/blog\/category\/berita\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#listItem","name":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#listItem","position":3,"name":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3","previousItem":{"@type":"ListItem","@id":"https:\/\/www.nanovest.io/blog\/category\/berita\/#listItem","name":"Berita"}}]},{"@type":"NewsArticle","@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#newsarticle","name":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita","headline":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3","author":{"@id":"https:\/\/www.nanovest.io/blog\/author\/maretha\/#author"},"publisher":{"@id":"https:\/\/www.nanovest.io/blog\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp","width":1536,"height":1024,"caption":"Bottle labeled 'Personalized mRNA Cancer Vaccine' on a lab bench with a shield graphic; DNA strand nearby and a muscular figure in the background, science imagery suggesting cancer treatment research."},"datePublished":"2026-08-20T10:48:10+07:00","dateModified":"2026-08-20T10:48:10+07:00","inLanguage":"id-ID","mainEntityOfPage":{"@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#webpage"},"isPartOf":{"@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#webpage"},"articleSection":"Berita, Saham AS, Berita, Saham Amerika, Saham AS, US Stocks","dateline":"Published on Agustus 20, 2026."},{"@type":"Organization","@id":"https:\/\/www.nanovest.io/blog\/#organization","name":"Nanovest","description":"Artikel dan Berita Kripto, Saham AS, dan Emas","url":"https:\/\/www.nanovest.io/blog\/","logo":{"@type":"ImageObject","url":"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2023\/03\/site-logo-color.png","@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#organizationLogo","width":250,"height":250,"caption":"site-logo-color"},"image":{"@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/nanovest","https:\/\/twitter.com\/nanovest_io","https:\/\/www.instagram.com\/nanovest.io\/","https:\/\/www.youtube.com\/channel\/UC5Y5fD2FApTWMc0c2mlxzIg","https:\/\/www.linkedin.com\/company\/nano-vest\/"]},{"@type":"Person","@id":"https:\/\/www.nanovest.io/blog\/author\/maretha\/#author","url":"https:\/\/www.nanovest.io/blog\/author\/maretha\/","name":"Maretha Putri","image":{"@type":"ImageObject","@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#authorImage","url":"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2026\/04\/cropped-ChatGPT-Image-Apr-6-2026-12_10_31-PM-96x96.png","width":96,"height":96,"caption":"Maretha Putri"}},{"@type":"WebPage","@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#webpage","url":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/","name":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita","description":"Vaksin kanker personalisasi Moderna dan Merck mencatat hasil positif dalam uji Fase 3 melanoma. Saham MRNA meroket 177%, sementara MRK ikut menguat.","inLanguage":"id-ID","isPartOf":{"@id":"https:\/\/www.nanovest.io/blog\/#website"},"breadcrumb":{"@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#breadcrumblist"},"author":{"@id":"https:\/\/www.nanovest.io/blog\/author\/maretha\/#author"},"creator":{"@id":"https:\/\/www.nanovest.io/blog\/author\/maretha\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp","@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#mainImage","width":1536,"height":1024,"caption":"Bottle labeled 'Personalized mRNA Cancer Vaccine' on a lab bench with a shield graphic; DNA strand nearby and a muscular figure in the background, science imagery suggesting cancer treatment research."},"primaryImageOfPage":{"@id":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/#mainImage"},"datePublished":"2026-08-20T10:48:10+07:00","dateModified":"2026-08-20T10:48:10+07:00"},{"@type":"WebSite","@id":"https:\/\/www.nanovest.io/blog\/#website","url":"https:\/\/www.nanovest.io/blog\/","name":"Nanovest","alternateName":"Blog Nanovest","description":"Artikel dan Berita Kripto, Saham AS, dan Emas","inLanguage":"id-ID","publisher":{"@id":"https:\/\/www.nanovest.io/blog\/#organization"}}]},"og:locale":"id_ID","og:site_name":"Blog Nanovest - Artikel dan Berita Kripto, Saham AS, dan Emas","og:type":"article","og:title":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita","og:description":"Vaksin kanker personalisasi Moderna dan Merck mencatat hasil positif dalam uji Fase 3 melanoma. Saham MRNA meroket 177%, sementara MRK ikut menguat.","og:url":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/","og:image":"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp","og:image:secure_url":"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp","og:image:width":1536,"og:image:height":1024,"article:published_time":"2026-08-20T03:48:10+00:00","article:modified_time":"2026-08-20T03:48:10+00:00","article:publisher":"https:\/\/www.facebook.com\/nanovest","twitter:card":"summary_large_image","twitter:site":"@nanovest_io","twitter:title":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3 - Berita","twitter:description":"Vaksin kanker personalisasi Moderna dan Merck mencatat hasil positif dalam uji Fase 3 melanoma. Saham MRNA meroket 177%, sementara MRK ikut menguat.","twitter:creator":"@nanovest_io","twitter:image":"https:\/\/www.nanovest.io/blog\/wp-content\/uploads\/2026\/08\/ChatGPT-Image-Aug-20-2026-10_41_35-AM-2.webp"},"aioseo_meta_data":{"post_id":"24388","title":"#post_title #separator_sa Berita","description":"Vaksin kanker personalisasi Moderna dan Merck mencatat hasil positif dalam uji Fase 3 melanoma. Saham MRNA meroket 177%, sementara MRK ikut menguat.","keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":{"category":80},"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":true,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"NewsArticle","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"seo_analyzer_scan_date":"2026-08-20 03:48:37","breadcrumb_settings":null,"limit_modified_date":false,"reviewed_by":null,"open_ai":null,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-08-20 03:40:28","updated":"2026-08-20 04:41:46","focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.nanovest.io/blog\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.nanovest.io/blog\/category\/berita\/\" title=\"Berita\">Berita<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\tVaksin Kanker Moderna-Merck Lolos Uji Fase 3\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.nanovest.io/blog"},{"label":"Berita","link":"https:\/\/www.nanovest.io/blog\/category\/berita\/"},{"label":"Vaksin Kanker Moderna-Merck Lolos Uji Fase 3","link":"https:\/\/www.nanovest.io/blog\/berita\/vaksin-kanker-moderna-merck-lolos-uji-24388\/"}],"_links":{"self":[{"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/posts\/24388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/comments?post=24388"}],"version-history":[{"count":1,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/posts\/24388\/revisions"}],"predecessor-version":[{"id":24390,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/posts\/24388\/revisions\/24390"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/media\/24389"}],"wp:attachment":[{"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/media?parent=24388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/categories?post=24388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nanovest.io/blog\/wp-json\/wp\/v2\/tags?post=24388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}